Friday, 12 December 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 12 December 2025
News

$672M sale saga ends... maybe

Posted 11 December 2025 PM

Mayne Pharma has terminated the Scheme Implementation Deed with US-based Cosette, bringing to an official end the planned $672 million sale of the Aussie company - but the saga looks like it could roll on.

In an ASX announcement this morning, Mayne said it would not be paying a "break fee" for bringing the drama-filled failed acquisition to a close and hinted there could be more legal action.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (11)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (1)

Devices (1)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.